Does oral semaglutide reduce heart attacks and strokes in high-risk diabetes patients?

Original title: Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Darren K. McGuire, Nikolaus Marx, Sharon L. Mulvagh +15 moreNew England Journal of Medicine2025-03-29DOI

Study Type

Clinical Trial

Semaglutide Type 2 Diabetes Cardiovascular Disease

Overview

In Plain Language

Oral semaglutide reduced major heart and vascular events in people with type 2 diabetes and high cardiovascular risk without increasing serious side effects.

Clinical trial

Methodology at a Glance

Control

Placebo

Preregistered

NCT03914326

Does oral semaglutide reduce heart attacks and strokes in high-risk diabetes patients?

Overview

In Plain Language

Methodology at a Glance

Findings

Quality Assessment

Caution Meter

Study Interrogation

Quality Checklist

Media Coverage

Learn About This Study

Does oral semaglutide reduce heart attacks and strokes in high-risk diabetes patients?

Overview

In Plain Language

Methodology at a Glance

Findings

Quality Assessment

Caution Meter

Study Interrogation

Quality Checklist

Media Coverage

Learn About This Study

What is a Randomized Controlled Trial (RCT)?

Understanding Sample Size

Funding & Conflicts of Interest

Why Preregistration Matters

Why Blinding Matters